Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
Charged with protecting the innovation arising from MedImmune, the global biologics research and development arm of AstraZeneca, as well as AstraZeneca’s innovative medicines and early development biotech units, Scott Alban’s job is far from insignificant.
Alban was behind AstraZeneca and MedImmune’s recent transformation of its global IP organisation to circumvent geographic and cultural barriers between the IP professionals who support pharmaceuticals and biologics across seven global sites.
“We wanted to empower our attorneys and other patent professionals to work collaboratively across multiple therapy areas, technology platforms and therapeutic modalities,” he says.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Scott Alban, LSIPR 50 2018, AstraZeneca, MedImmune, biology, research and development, innovation, biotech